SAN DIEGO, April 29, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report first quarter 2011 financial results on Friday, May 6, 2011 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PDT (11:00 a.m. EDT), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the first quarter of 2011 and provide a product pipeline update.
To participate by telephone, please dial 877.407.8037 for domestic callers or 201.689.8037 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme's Web site for seven days. A telephone replay will be available by dialing 877.660.6853 from the U.S., or 201.612.7415 for international callers and using account # 367 and ID # 371588.
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche and Baxter to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, and immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Robert H. Uhl
Senior Director, Investor Relations
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved